Among the GIST patients who progressed on TKI therapy evaluated in our study, we identified a potentially actionable acquired PIK3CA exon 9 c.1633G>A variant in NCCS-GIST-17 upon resistance to imatinib. Here, PIK3CA is linked to gastrointestinal stromal tumor.